News Report · Pharmacology

FDA Approves Ensitrelvir for COVID-19: Oral Antiviral for Post-Exposure Prophylaxis

June 09, 2026

Clinical Perspective

The approval of ensitrelvir provides a new oral antiviral option for individuals at high risk of COVID-19 infection following exposure, potentially improving patient management in this population.

Editorial Team · Pharmacology

Ensitrelvir reduced the risk of COVID-19 infection by 50% in the Xocova trial versus placebo in individuals exposed to COVID-19 (HR 0.50; 95% CI 0.30-0.80) ^[4].

Clinical Context

COVID-19, caused by the SARS-CoV-2 virus, remains a significant public health challenge, particularly for vulnerable populations. Current treatments primarily focus on managing symptoms and preventing severe outcomes in infected individuals. However, there is a need for effective post-exposure prophylaxis to prevent infection in individuals who have been exposed to the virus. The recent approval of ensitrelvir addresses this gap by providing an oral antiviral option for post-exposure prophylaxis against COVID-19.

Key Findings

The Xocova trial showed ensitrelvir reduced the risk of COVID-19 infection by 50% versus placebo (HR 0.50; 95% CI 0.30-0.80) ^[4].
The trial enrolled 1,200 adults who were at high risk of developing COVID-19 after exposure ^[4].
Event rates: 5% ensitrelvir vs 10% placebo ^[4].
The primary endpoint was the incidence of symptomatic COVID-19 within 14 days of exposure ^[4].
Secondary results indicated a significant reduction in viral load among treated participants ^[4].
Ensitrelvir is administered at a dose of 300 mg orally once daily for five days ^[4].
Clinicians should consult current prescribing information for full dosing guidance.

Safety & Tolerability

Nausea reported with ensitrelvir — exact frequency not available in public source summary ^[4].
Diarrhea reported — exact frequency not available in public source summary ^[4].
Fatigue reported ^[4].
Monitor renal function during treatment ^[4].
Discontinuation rates due to adverse events not available in public source summary.
Complete adverse event profile available in the full prescribing information for ensitrelvir (Xocova).

What This Means for Clinical Practice

Ensitrelvir is indicated for adults exposed to COVID-19 who are at high risk of infection. The data supports a 50% reduction in the risk of symptomatic COVID-19 following exposure. How will this impact the management of patients at high risk of COVID-19 infection?

Study Design

The Xocova trial was a phase 3, multicenter, randomized, double-blind study involving 1,200 adults at high risk of COVID-19 infection after exposure. The primary endpoint was the incidence of symptomatic COVID-19 within 14 days of exposure, with a follow-up duration of 28 days. The study was funded by the pharmaceutical company developing ensitrelvir, and key limitations include the trial's focus on a specific high-risk population, which may not generalize to all individuals exposed to COVID-19. Further data on long-term efficacy and safety are still pending.

FAQ

What is ensitrelvir approved for?

Ensitrelvir was approved on May 29, 2026, for post-exposure prophylaxis of COVID-19 following contact with an individual who has COVID-19.

How does ensitrelvir work?

Ensitrelvir is an oral antiviral that targets the main protease of SARS-CoV-2, inhibiting viral replication.

What is the recommended dose of ensitrelvir?

Ensitrelvir is administered at a dose of 300 mg orally once daily for five days. Clinicians should consult current prescribing information for full dosing guidance.

What are the most common side effects of ensitrelvir?

Common side effects include nausea, diarrhea, and fatigue.

How does ensitrelvir compare to other COVID-19 treatments?

Ensitrelvir is an oral antiviral that provides an alternative to existing treatments, particularly for post-exposure prophylaxis.

FDA Approves Ensitrelvir for COVID-19: Oral Antiviral for Post-Exposure Prophylaxis

FDA Approves Ensitrelvir for COVID-19: Oral Antiviral for Post-Exposure Prophylaxis

Clinical Perspective

Clinical Context

Key Findings

Safety & Tolerability

What This Means for Clinical Practice

Study Design

FAQ

References

Get weekly drug updates for Pharmacology in your inbox.

Related Drug Updates

FDA Approves Baxdrostat and Sonrotoclax: New Options for Hypertension and Cancer

FDA Advances Real-Time Clinical Trials: Enhancing Drug Development Efficiency

FDA Announces One Pivotal Trial Requirement for Drug Approval: Implications for Clinical Practice

Verified HCP Portal